**COVID-19 Outpatient Therapeutics Decision Guide**

**New Resource**

**COVID-19 Outpatient Therapeutics Decision Guide**

Adult or pediatric (age 12 and older and weight 40kg or greater) with mild to moderate COVID-19 & high risk for progression to severe disease

Is Patient:
- Hospitalized for COVID-19 OR
- Requiring O₂ OR an increase in baseline home O₂ due to COVID-19

No

Symptom onset within the past 5-7 days?

No

Symptom onset within the past 10 days?

Yes

Does patient have severe renal impairment (eGFR <30mL/min)
OR Severe hepatic impairment (Child-Pugh class C)

No

Consider the following (symptoms within 10 days)³:
- sotrovimab 500 mg IV [sotrovimab EUA]

Yes

Treatment of symptoms, Management per NIH & CDC Guidelines

Consider one of the following therapeutics, if available¹-³:
- Paxlovid within 5 days of symptom onset
- eGFR 60 mL/min or greater: 300mg nirmatrelvir taken with 100mg ritonavir twice daily for 5 days
- eGFR >30-<60: 150mg nirmatrelvir taken together with 100mg ritonavir twice daily for 5 days; evaluate concomitant use of CYP3A inducers and medications with high dependency on CYP3A for clearance as these may be contraindicated per Paxlovid EUA
- sotrovimab 500 mg IV within ASPA 10 days of symptom onset [sotrovimab EUA]
- Remdesivir 200mg IV x 1 dose on day 1, 100mg IV x 1 on days 2-3 begun ASPA and within 7 days of symptom onset²

No

If none of the above therapeutics are available for patient treatment within 5 days of symptom onset and patient is age 18 or greater

Possibility of pregnancy, if applicable, is ruled out?

Yes

Consider molnupiravir
- Authorized only in patients ages 18 and older
- Within 5 days of symptom onset
- Molnupiravir 800mg by mouth every 12h for 5 days
- Prescribers must review and comply with the mandatory requirements outlined in the molnupiravir EUA

No

Limited use of bamlanivimab/etesevimab and REGEN-COV as they are not expected to be active against the Omicron variant²


³December 30, 2021